Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

The cell of origin and the leukemia stem cell in acute myeloid leukemia.

Chopra M, Bohlander SK.

Genes Chromosomes Cancer. 2019 Aug 31. doi: 10.1002/gcc.22805. [Epub ahead of print]

PMID:
31471945
2.

Allelic Imbalance of Recurrently Mutated Genes in Acute Myeloid Leukaemia.

Batcha AMN, Bamopoulos SA, Kerbs P, Kumar A, Jurinovic V, Rothenberg-Thurley M, Ksienzyk B, Philippou-Massier J, Krebs S, Blum H, Schneider S, Konstandin N, Bohlander SK, Heckman C, Kontro M, Hiddemann W, Spiekermann K, Braess J, Metzeler KH, Greif PA, Mansmann U, Herold T.

Sci Rep. 2019 Aug 13;9(1):11796. doi: 10.1038/s41598-019-48167-4.

3.

Preface to special issue: Acute myeloid leukemia-Genetics, stem cells, clonal evolution, and new therapies.

Bohlander SK.

Genes Chromosomes Cancer. 2019 Aug 13. doi: 10.1002/gcc.22800. [Epub ahead of print] Review. No abstract available.

PMID:
31408244
4.

The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.

Angenendt L, Bormann E, Pabst C, Alla V, Görlich D, Braun L, Dohlich K, Schwöppe C, Bohlander SK, Arteaga MF, Wethmar K, Hartmann W, Angenendt A, Kessler T, Mesters RM, Stelljes M, Rothenberg-Thurley M, Spiekermann K, Hébert J, Sauvageau G, Valk PJM, Löwenberg B, Serve H, Müller-Tidow C, Lenz G, Wörmann BJ, Sauerland MC, Hiddemann W, Berdel WE, Krug U, Metzeler KH, Mikesch JH, Herold T, Schliemann C.

Leukemia. 2019 Jun 10. doi: 10.1038/s41375-019-0505-x. [Epub ahead of print]

PMID:
31182782
5.

CCAAT/enhancer-binding protein alpha (CEBPA) gene haploinsufficiency does not alter hematopoiesis or induce leukemia in Lck-CALM/AF10 transgenic mice.

Lange AP, Almeida LY, Araújo Silva CL, Scheucher PS, Chahud F, Krause A, Bohlander SK, Rego EM.

Braz J Med Biol Res. 2019;52(6):e8424. doi: 10.1590/1414-431X20198424. Epub 2019 May 27.

6.

Acute myeloid leukemia driven by the CALM-AF10 fusion gene is dependent on BMI1.

Barbosa K, Deshpande A, Chen BR, Ghosh A, Sun Y, Dutta S, Weetall M, Dixon J, Armstrong SA, Bohlander SK, Deshpande AJ.

Exp Hematol. 2019 Jun;74:42-51.e3. doi: 10.1016/j.exphem.2019.04.003. Epub 2019 May 13.

PMID:
31022428
7.

Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide.

Hunter FW, Devaux JBL, Meng F, Hong CR, Khan A, Tsai P, Ketela TW, Sharma I, Kakadia PM, Marastoni S, Shalev Z, Hickey AJR, Print CG, Bohlander SK, Hart CP, Wouters BG, Wilson WR.

Mol Pharmacol. 2019 Jun;95(6):638-651. doi: 10.1124/mol.118.115196. Epub 2019 Apr 12.

PMID:
30979813
8.

Derivation of Breast Cancer Cell Lines Under Physiological (5%) Oxygen Concentrations.

Leung EY, Askarian-Amiri ME, Singleton DC, Ferraro-Peyret C, Joseph WR, Finlay GJ, Broom RJ, Kakadia PM, Bohlander SK, Marshall E, Baguley BC.

Front Oncol. 2018 Oct 12;8:425. doi: 10.3389/fonc.2018.00425. eCollection 2018.

9.

Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA.

Konstandin NP, Pastore F, Herold T, Dufour A, Rothenberg-Thurley M, Hinrichsen T, Ksienzyk B, Tschuri S, Schneider S, Hoster E, Berdel WE, Woermann BJ, Sauerland MC, Braess J, Bohlander SK, Klein HG, Hiddemann W, Metzeler KH, Spiekermann K.

Blood Adv. 2018 Oct 23;2(20):2724-2731. doi: 10.1182/bloodadvances.2018016840.

10.

Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.

Braess J, Amler S, Kreuzer KA, Spiekermann K, Lindemann HW, Lengfelder E, Graeven U, Staib P, Ludwig WD, Biersack H, Ko YD, Uppenkamp MJ, De Wit M, Korsten S, Peceny R, Gaska T, Schiel X, Behringer DM, Kiehl MG, Zinngrebe B, Meckenstock G, Roemer E, Medgenberg D, Spaeth-Schwalbe E, Massenkeil G, Hindahl H, Schwerdtfeger R, Trenn G, Sauerland C, Koch R, Lablans M, Faldum A, Görlich D, Bohlander SK, Schneider S, Dufour A, Buske C, Fiegl M, Subklewe M, Braess B, Unterhalt M, Baumgartner A, Wörmann B, Beelen D, Hiddemann W; AML-CG.

Leukemia. 2018 Dec;32(12):2558-2571. doi: 10.1038/s41375-018-0268-9. Epub 2018 Oct 1.

11.

Efficient identification of somatic mutations in acute myeloid leukaemia using whole exome sequencing of fingernail derived DNA as germline control.

Kakadia PM, Van de Water N, Browett PJ, Bohlander SK.

Sci Rep. 2018 Sep 13;8(1):13751. doi: 10.1038/s41598-018-31503-5.

12.

Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.

Jamieson SM, Tsai P, Kondratyev MK, Budhani P, Liu A, Senzer NN, Chiorean EG, Jalal SI, Nemunaitis JJ, Kee D, Shome A, Wong WW, Li D, Poonawala-Lohani N, Kakadia PM, Knowlton NS, Lynch CR, Hong CR, Lee TW, Grénman RA, Caporiccio L, McKee TD, Zaidi M, Butt S, Macann AM, McIvor NP, Chaplin JM, Hicks KO, Bohlander SK, Wouters BG, Hart CP, Print CG, Wilson WR, Curran MA, Hunter FW.

JCI Insight. 2018 Aug 23;3(16). pii: 122204. doi: 10.1172/jci.insight.122204. eCollection 2018 Aug 23.

13.

Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia.

Hornung R, Jurinovic V, Batcha AMN, Bamopoulos SA, Rothenberg-Thurley M, Amler S, Sauerland MC, Berdel WE, Wörmann BJ, Bohlander SK, Braess J, Hiddemann W, Lehmann S, Mareschal S, Spiekermann K, Metzeler KH, Herold T, Boulesteix AL.

Sci Rep. 2018 Jul 26;8(1):11293. doi: 10.1038/s41598-018-29593-2.

14.

Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia.

Schranz K, Hubmann M, Harin E, Vosberg S, Herold T, Metzeler KH, Rothenberg-Thurley M, Janke H, Bräundl K, Ksienzyk B, Batcha AMN, Schaaf S, Schneider S, Bohlander SK, Görlich D, Berdel WE, Wörmann BJ, Braess J, Krebs S, Hiddemann W, Mansmann U, Spiekermann K, Greif PA.

Oncotarget. 2018 Jul 10;9(53):30128-30145. doi: 10.18632/oncotarget.25729. eCollection 2018 Jul 10.

15.

Relapse of acute myeloid leukemia after allogeneic stem cell transplantation is associated with gain of WT1 alterations and high mutation load.

Vosberg S, Hartmann L, Metzeler KH, Konstandin NP, Schneider S, Varadharajan A, Hauser A, Krebs S, Blum H, Bohlander SK, Hiddemann W, Tischer J, Spiekermann K, Greif PA.

Haematologica. 2018 Dec;103(12):e581-e584. doi: 10.3324/haematol.2018.193102. Epub 2018 Jun 28. No abstract available.

16.

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older.

Prassek VV, Rothenberg-Thurley M, Sauerland MC, Herold T, Janke H, Ksienzyk B, Konstandin NP, Goerlich D, Krug U, Faldum A, Berdel WE, Wörmann B, Braess J, Schneider S, Subklewe M, Bohlander SK, Hiddemann W, Spiekermann K, Metzeler KH.

Haematologica. 2018 Nov;103(11):1853-1861. doi: 10.3324/haematol.2018.191536. Epub 2018 Jun 14.

17.

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.

Rothenberg-Thurley M, Amler S, Goerlich D, Köhnke T, Konstandin NP, Schneider S, Sauerland MC, Herold T, Hubmann M, Ksienzyk B, Zellmeier E, Bohlander SK, Subklewe M, Faldum A, Hiddemann W, Braess J, Spiekermann K, Metzeler KH.

Leukemia. 2018 Jul;32(7):1598-1608. doi: 10.1038/s41375-018-0034-z. Epub 2018 Feb 23.

18.

Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients.

Greif PA, Hartmann L, Vosberg S, Stief SM, Mattes R, Hellmann I, Metzeler KH, Herold T, Bamopoulos SA, Kerbs P, Jurinovic V, Schumacher D, Pastore F, Bräundl K, Zellmeier E, Ksienzyk B, Konstandin NP, Schneider S, Graf A, Krebs S, Blum H, Neumann M, Baldus CD, Bohlander SK, Wolf S, Görlich D, Berdel WE, Wörmann BJ, Hiddemann W, Spiekermann K.

Clin Cancer Res. 2018 Apr 1;24(7):1716-1726. doi: 10.1158/1078-0432.CCR-17-2344. Epub 2018 Jan 12.

19.

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.

Rothenberg-Thurley M, Amler S, Goerlich D, Köhnke T, Konstandin NP, Schneider S, Sauerland MC, Herold T, Hubmann M, Ksienzyk B, Zellmeier E, Bohlander SK, Subklewe M, Faldum A, Hiddemann W, Braess J, Spiekermann K, Metzeler KH.

Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.350. [Epub ahead of print]

PMID:
29249818
20.

A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia.

Herold T, Jurinovic V, Batcha AMN, Bamopoulos SA, Rothenberg-Thurley M, Ksienzyk B, Hartmann L, Greif PA, Phillippou-Massier J, Krebs S, Blum H, Amler S, Schneider S, Konstandin N, Sauerland MC, Görlich D, Berdel WE, Wörmann BJ, Tischer J, Subklewe M, Bohlander SK, Braess J, Hiddemann W, Metzeler KH, Mansmann U, Spiekermann K.

Haematologica. 2018 Mar;103(3):456-465. doi: 10.3324/haematol.2017.178442. Epub 2017 Dec 14.

21.

A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.

Beck D, Thoms JAI, Palu C, Herold T, Shah A, Olivier J, Boelen L, Huang Y, Chacon D, Brown A, Babic M, Hahn C, Perugini M, Zhou X, Huntly BJ, Schwarzer A, Klusmann JH, Berdel WE, Wörmann B, Büchner T, Hiddemann W, Bohlander SK, To LB, Scott HS, Lewis ID, D'Andrea RJ, Wong JWH, Pimanda JE.

Leukemia. 2018 Feb;32(2):263-272. doi: 10.1038/leu.2017.210. Epub 2017 Jul 4.

PMID:
28674423
22.

A fluorescence in situ hybridization-based screen allows rapid detection of adverse cytogenetic alterations in patients with acute myeloid leukemia.

Sandhöfer N, Metzeler KH, Kakadia PM, Pasalic Z, Hiddemann W, Neusser M, Steinlein O, Fiegl M, Subklewe M, Spiekermann K, Bohlander SK, Schneider S, Braess J.

Genes Chromosomes Cancer. 2017 Aug;56(8):632-638. doi: 10.1002/gcc.22466. Epub 2017 May 19.

PMID:
28420034
23.

Variable aldehyde dehydrogenase activity and effects on chemosensitivity of primitive human leukemic cells.

Bogen A, Buske C, Hiddemann W, Bohlander SK, Christ O.

Exp Hematol. 2017 Mar;47:54-63. doi: 10.1016/j.exphem.2016.10.012. Epub 2016 Nov 5.

PMID:
27826122
24.

An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL.

Kakadia PM, Schmidmaier R, Völkl A, Schneider I, Huk N, Schneider S, Panzner G, Neidel U, Fritz B, Spiekermann K, Bohlander SK.

Leuk Res Rep. 2016 Oct 14;6:50-54. eCollection 2016.

25.

Complement cascade gene expression defines novel prognostic subgroups of acute myeloid leukemia.

Laverdière I, Boileau M, Herold T, Rak J, Berdel WE, Wörmann B, Hiddemann W, Spiekermann K, Bohlander SK, Eppert K.

Exp Hematol. 2016 Nov;44(11):1039-1043.e10. doi: 10.1016/j.exphem.2016.07.012. Epub 2016 Jul 26.

PMID:
27473565
26.

Acute myeloid leukemia with del(9q) is characterized by frequent mutations of NPM1, DNMT3A, WT1 and low expression of TLE4.

Herold T, Metzeler KH, Vosberg S, Hartmann L, Jurinovic V, Opatz S, Konstandin NP, Schneider S, Zellmeier E, Ksienzyk B, Graf A, Krebs S, Blum H, Cristina Sauerland M, Büchner T, Berdel WE, Wörmann BJ, Mansmann U, Hiddemann W, Bohlander SK, Spiekermann K, Greif PA.

Genes Chromosomes Cancer. 2017 Jan;56(1):75-86. doi: 10.1002/gcc.22418. Epub 2016 Oct 25.

PMID:
27636548
27.

CATS (FAM64A) abnormal expression reduces clonogenicity of hematopoietic cells.

Barbutti I, Xavier-Ferrucio JM, Machado-Neto JA, Ricon L, Traina F, Bohlander SK, Saad ST, Archangelo LF.

Oncotarget. 2016 Oct 18;7(42):68385-68396. doi: 10.18632/oncotarget.11724.

28.

Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis.

Herold T, Schneider S, Metzeler KH, Neumann M, Hartmann L, Roberts KG, Konstandin NP, Greif PA, Bräundl K, Ksienzyk B, Huk N, Schneider I, Zellmeier E, Jurinovic V, Mansmann U, Hiddemann W, Mullighan CG, Bohlander SK, Spiekermann K, Hoelzer D, Brüggemann M, Baldus CD, Dreyling M, Gökbuget N.

Haematologica. 2017 Jan;102(1):130-138. doi: 10.3324/haematol.2015.136366. Epub 2016 Aug 25.

29.

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.

Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Görlich D, Schneider S, Konstandin NP, Dufour A, Bräundl K, Ksienzyk B, Zellmeier E, Hartmann L, Greif PA, Fiegl M, Subklewe M, Bohlander SK, Krug U, Faldum A, Berdel WE, Wörmann B, Büchner T, Hiddemann W, Braess J, Spiekermann K; AMLCG Study Group.

Blood. 2016 Aug 4;128(5):686-98. doi: 10.1182/blood-2016-01-693879. Epub 2016 Jun 10.

30.

Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles.

Jiang X, Bugno J, Hu C, Yang Y, Herold T, Qi J, Chen P, Gurbuxani S, Arnovitz S, Strong J, Ferchen K, Ulrich B, Weng H, Wang Y, Huang H, Li S, Neilly MB, Larson RA, Le Beau MM, Bohlander SK, Jin J, Li Z, Bradner JE, Hong S, Chen J.

Cancer Res. 2016 Aug 1;76(15):4470-80. doi: 10.1158/0008-5472.CAN-15-2949. Epub 2016 Jun 8.

31.

ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation.

Hartmann L, Dutta S, Opatz S, Vosberg S, Reiter K, Leubolt G, Metzeler KH, Herold T, Bamopoulos SA, Bräundl K, Zellmeier E, Ksienzyk B, Konstandin NP, Schneider S, Hopfner KP, Graf A, Krebs S, Blum H, Middeke JM, Stölzel F, Thiede C, Wolf S, Bohlander SK, Preiss C, Chen-Wichmann L, Wichmann C, Sauerland MC, Büchner T, Berdel WE, Wörmann BJ, Braess J, Hiddemann W, Spiekermann K, Greif PA.

Nat Commun. 2016 Jun 2;7:11733. doi: 10.1038/ncomms11733.

32.

miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia.

Jiang X, Hu C, Arnovitz S, Bugno J, Yu M, Zuo Z, Chen P, Huang H, Ulrich B, Gurbuxani S, Weng H, Strong J, Wang Y, Li Y, Salat J, Li S, Elkahloun AG, Yang Y, Neilly MB, Larson RA, Le Beau MM, Herold T, Bohlander SK, Liu PP, Zhang J, Li Z, He C, Jin J, Hong S, Chen J.

Nat Commun. 2016 Apr 26;7:11452. doi: 10.1038/ncomms11452.

33.

Close correlation of copy number aberrations detected by next-generation sequencing with results from routine cytogenetics in acute myeloid leukemia.

Vosberg S, Herold T, Hartmann L, Neumann M, Opatz S, Metzeler KH, Schneider S, Graf A, Krebs S, Blum H, Baldus CD, Hiddemann W, Spiekermann K, Bohlander SK, Mansmann U, Greif PA.

Genes Chromosomes Cancer. 2016 Jul;55(7):553-67. doi: 10.1002/gcc.22359. Epub 2016 May 2.

PMID:
27015608
34.

GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo.

Pabst C, Bergeron A, Lavallée VP, Yeh J, Gendron P, Norddahl GL, Krosl J, Boivin I, Deneault E, Simard J, Imren S, Boucher G, Eppert K, Herold T, Bohlander SK, Humphries K, Lemieux S, Hébert J, Sauvageau G, Barabé F.

Blood. 2016 Apr 21;127(16):2018-27. doi: 10.1182/blood-2015-11-683649. Epub 2016 Feb 1.

35.

The target cell of transformation is distinct from the leukemia stem cell in murine CALM/AF10 leukemia models.

Dutta S, Krause A, Vosberg S, Herold T, Ksienzyk B, Quintanilla-Martinez L, Tizazu B, Chopra M, Graf A, Krebs S, Blum H, Greif PA, Vetter A, Metzeler K, Rothenberg-Thurley M, Schneider MR, Dahlhoff M, Spiekermann K, Zimber-Strobl U, Wolf E, Bohlander SK.

Leukemia. 2016 May;30(5):1166-76. doi: 10.1038/leu.2015.349. Epub 2015 Dec 21.

PMID:
26686248
36.

A 4-gene expression score associated with high levels of Wilms Tumor-1 (WT1) expression is an adverse prognostic factor in acute myeloid leukaemia.

Niavarani A, Herold T, Reyal Y, Sauerland MC, Buchner T, Hiddemann W, Bohlander SK, Valk PJ, Bonnet D.

Br J Haematol. 2016 Feb;172(3):401-11. doi: 10.1111/bjh.13836. Epub 2015 Nov 24.

37.

DNA Repair and Chromosomal Translocations.

Bohlander SK, Kakadia PM.

Recent Results Cancer Res. 2015;200:1-37. doi: 10.1007/978-3-319-20291-4_1. Review.

PMID:
26376870
38.

Inhibition of glutamate regulated calcium entry into leukemic megakaryoblasts reduces cell proliferation and supports differentiation.

Kamal T, Green TN, Morel-Kopp MC, Ward CM, McGregor AL, McGlashan SR, Bohlander SK, Browett PJ, Teague L, During MJ, Skerry TM, Josefsson EC, Kalev-Zylinska ML.

Cell Signal. 2015 Sep;27(9):1860-72. doi: 10.1016/j.cellsig.2015.05.004. Epub 2015 May 14.

PMID:
25982509
39.

Mutations in SEC24D, encoding a component of the COPII machinery, cause a syndromic form of osteogenesis imperfecta.

Garbes L, Kim K, Rieß A, Hoyer-Kuhn H, Beleggia F, Bevot A, Kim MJ, Huh YH, Kweon HS, Savarirayan R, Amor D, Kakadia PM, Lindig T, Kagan KO, Becker J, Boyadjiev SA, Wollnik B, Semler O, Bohlander SK, Kim J, Netzer C.

Am J Hum Genet. 2015 Mar 5;96(3):432-9. doi: 10.1016/j.ajhg.2015.01.002. Epub 2015 Feb 12.

40.

Mutational spectrum of adult T-ALL.

Neumann M, Vosberg S, Schlee C, Heesch S, Schwartz S, Gökbuget N, Hoelzer D, Graf A, Krebs S, Bartram I, Blum H, Brüggemann M, Hecht J, Bohlander SK, Greif PA, Baldus CD.

Oncotarget. 2015 Feb 20;6(5):2754-66.

41.

Disturbing the histone code in leukemia: translocations and mutations affecting histone methyl transferases.

Chopra M, Bohlander SK.

Cancer Genet. 2015 May;208(5):192-205. doi: 10.1016/j.cancergen.2014.10.005. Epub 2014 Oct 27. Review.

PMID:
25592767
42.

Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia.

Alachkar H, Mutonga MB, Metzeler KH, Fulton N, Malnassy G, Herold T, Spiekermann K, Bohlander SK, Hiddemann W, Matsuo Y, Stock W, Nakamura Y.

Oncotarget. 2014 Dec 15;5(23):12371-82.

43.

Identification and characterization of OSTL (RNF217) encoding a RING-IBR-RING protein adjacent to a translocation breakpoint involving ETV6 in childhood ALL.

Fontanari Krause LM, Japp AS, Krause A, Mooster J, Chopra M, Müschen M, Bohlander SK.

Sci Rep. 2014 Oct 9;4:6565. doi: 10.1038/srep06565.

44.

Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis.

Herold T, Metzeler KH, Vosberg S, Hartmann L, Röllig C, Stölzel F, Schneider S, Hubmann M, Zellmeier E, Ksienzyk B, Jurinovic V, Pasalic Z, Kakadia PM, Dufour A, Graf A, Krebs S, Blum H, Sauerland MC, Büchner T, Berdel WE, Woermann BJ, Bornhäuser M, Ehninger G, Mansmann U, Hiddemann W, Bohlander SK, Spiekermann K, Greif PA.

Blood. 2014 Aug 21;124(8):1304-11. doi: 10.1182/blood-2013-12-540716. Epub 2014 Jun 12.

45.

Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.

Köhnke T, Sauter D, Ringel K, Hoster E, Laubender RP, Hubmann M, Bohlander SK, Kakadia PM, Schneider S, Dufour A, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Spiekermann K, Subklewe M.

Leukemia. 2015 Feb;29(2):377-86. doi: 10.1038/leu.2014.186. Epub 2014 Jun 10.

PMID:
24912430
46.

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.

Hubmann M, Köhnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, Fiegl M, Braess J, Bohlander SK, Subklewe M, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Hiddemann W, Spiekermann K.

Haematologica. 2014 Aug;99(8):1317-25. doi: 10.3324/haematol.2014.104133. Epub 2014 May 9.

47.

Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia.

Pastore F, Dufour A, Benthaus T, Metzeler KH, Maharry KS, Schneider S, Ksienzyk B, Mellert G, Zellmeier E, Kakadia PM, Unterhalt M, Feuring-Buske M, Buske C, Braess J, Sauerland MC, Heinecke A, Krug U, Berdel WE, Buechner T, Woermann B, Hiddemann W, Bohlander SK, Marcucci G, Spiekermann K, Bloomfield CD, Hoster E.

J Clin Oncol. 2014 May 20;32(15):1586-94. doi: 10.1200/JCO.2013.52.3480. Epub 2014 Apr 7.

48.

Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.

Janke H, Pastore F, Schumacher D, Herold T, Hopfner KP, Schneider S, Berdel WE, Büchner T, Woermann BJ, Subklewe M, Bohlander SK, Hiddemann W, Spiekermann K, Polzer H.

PLoS One. 2014 Mar 7;9(3):e89560. doi: 10.1371/journal.pone.0089560. eCollection 2014.

49.

A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.

Jamieson SM, Gu Y, Manesh DM, El-Hoss J, Jing D, Mackenzie KL, Guise CP, Foehrenbacher A, Pullen SM, Benito J, Smaill JB, Patterson AV, Mulaw MA, Konopleva M, Bohlander SK, Lock RB, Wilson WR.

Biochem Pharmacol. 2014 Mar 1;88(1):36-45. doi: 10.1016/j.bcp.2013.12.019. Epub 2014 Jan 13.

PMID:
24434189
50.

ABCs of genomics.

Bohlander SK.

Hematology Am Soc Hematol Educ Program. 2013;2013:316-23. doi: 10.1182/asheducation-2013.1.316. Review.

PMID:
24319198

Supplemental Content

Loading ...
Support Center